Preclinical studies suggest that combined inhibition of PD-1 and CSF1 receptor (CSF1R) can lead to tumor regression by depleting immunosuppressive and pro-tumorigenic TAMs, offering a strategy to counter CSF1-induced resistance (226). The gene discussed is PDCD1; the disease is neoplasm.